ESTIMATED COST MODEL PATIENT BREAST CANCER DRUGS AND DETERMINANTS IN HOSPITAL IN INDONESIA
ABSTRACT: Currently non communicable disease becomes one of the ten major diseases in Indonesia. While cancer chemotheraphy reported as the ninth rank out of ten major diseases for in-patient cases. And from the ten most expensive hospital cost, breast cancer has shared at the tenth position. By the expenditure component, drugs expenditures are clearly the main source of cost pressure. Only a few studies were found related to drug cost model and breast cancer drug, and they were much focused on cost effectiveness, cost utility ratio and incremental cost. Therefore, it is important to know the drug cost of breast cancer in Indonesia. their associated factors and the magnitude of the factors. The research need to know on how to estimate drug cost for breast cancer during hospitalization in Indonesia. Several questions derived from the main questions, they were : what are the influencing factors, the magnitude of each factors, and how to formulate drug cost modeling for breast cancer. The design of research was a cross sectional descriptive analysis using health facilities costing study that was conducted in Indonesia in 2011. The drug cost model was formulated as a cost of illness employing the prevalence based approach from a provider’s perspective. Based on the fitted model, the significant predictor variables include patient characteristics (age, length of stay, ICU facility usage), hospital characteristics (drug supply problem), hospital location (Java and non-Java). The formula is s follows : Ln drug cost = 12.03 + (0.03 X % patient age 40-<70) - (0,66 X % patient age ≥70) + (0,09 X average length of stay) + (0,98 X % patient using ICU ) + (0,86 X % patient at hospital without drug supply problem) + (1,01 X % patient hospitalized out of Java ). Based on model and calculation, drug cost for breast cancer per patient per year was Rp 9.882.067,- and total drug cost for all patient per year was Rp 118.723.158.312,-.
